Brahim Achour, MPharm, PhD

  • Assistant Professor
  • Office: 495A Lab: 490
  • Phone: 401.874.9379
  • Email:
  • Office Location: Avedisian Hall, 7 Greenhouse Road, Kingston, RI, 02881


Dr Achour’s research focuses on the study of pharmacokinetics and pharmacodynamics in special and disease populations using clinical and translational modelling tools and the development of precision medicine approaches to enable individualized pharmacological therapy.



Master of Pharmacy (UK Pharmacy degree), School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK – 2007

PhD in Pharmacology, Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester, UK – 2013

Professional Experience

March 2022-Present: Assistant Professor, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island

May 2014-March 2022: Post-doctoral Research Fellow, Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK

Selected Publications

Achour B, Gosselin P, Terrier J, Gloor Y, Al-Majdoub ZM, Polasek TM, Daali Y, Rostami-Hodjegan Y, Reny J-L. 2022. Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P-glycoprotein activities. Clinical Pharmacology and Therapeutics, 111(6): 1268–1277.

Vasilogianni A-M, El-Khateeb E, Al-Majdoub ZM, Alrubia S, Rostami-Hodjegan A, Barber J, Achour B*. 2022. Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease. Journal of Proteomics, 263, 104601.

Alrubia S, Al-Majdoub ZM, Achour B, Rostami-Hodjegan A, Barber J. 2022. Quantitative assessment of the impact of Crohn’s disease on protein abundance of human intestinal drug-metabolising enzymes and transporters. Journal of Pharmaceutical Sciences, DOI: 10.1016/j.xphs.2022.07.012.

Vasilogianni A-M, Al-Majdoub ZM, Achour B, Peters SA, Barber J, Rostami-Hodjegan A. 2022. Quantitative proteomics of hepatic drug-metabolizing enzymes and transporters in patients with colorectal cancer metastasis. Clinical Pharmacology and Therapeutics, DOI: 10.1002/cpt.2633.

Vasilogianni A-M, Al-Majdoub ZM, Achour B, Peters SA, Rostami-Hodjegan A, Barber J. 2022. Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects. British Journal of Clinical Pharmacology, 88(4): 1811–1823.

El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. 2021. Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: Implications for drug dosage adjustment. Molecular Pharmaceutics, 18(9): 3563–3577.

Al-Majdoub Z, Scotcher D, Achour B, Barber J, Galetin A, Rostami-Hodjegan A. 2021. Quantitative proteomic map of enzymes and transporters in the human kidney: Stepping closer to mechanistic kidney models to define local kinetics. Clinical Pharmacology and Therapeutics, 110(5): 1389–1400.

El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A. 2021. Time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Alimentary Pharmacology and Therapeutics, 54(4): 388-401.

Vasilogianni A-M, Achour B, Scotcher D, Peters SA, Al-Majdoub Z, Barber J, Rostami-Hodjegan A. 2021. Hepatic scaling factors for in vitro-in vivo extrapolation (IVIVE) of metabolic drug clearance in patients with colorectal cancer with liver metastasis. Drug Metabolism and Disposition, 49(7): 563-571.

Neuhoff S, Harwood MD, Rostami-Hodjegan A, Achour B*. 2021. Application of proteomic data in the translation of in vitro observations to associated clinical outcomes. Drug Discovery Today: Technologies, 39: 13-22.

Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, Reny J-L, Daali Y, Eiermann B, Cook J, Lesko L, McLachlan A, Rostami-Hodjegan A. 2021. Model-informed precision dosing: background, requirements, validation, implementation and forward trajectory of individualizing drug therapy. Annual Review of Pharmacology and Toxicology, 61(1): 225-245.

Achour B, Al-Majdoub ZM, Grybos-Gajniak A, Lea K, Kilford P, Zhang M, Knight D, Barber J, Schageman J, Rostami-Hodjegan A. 2021. Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clinical Pharmacology and Therapeutics, 109(1): 222-232.

Al-Majdoub ZM, Couto N, Achour B, Harwood MD, Carlson GL, Warhurst G, Barber J, Rostami-Hodjegan A. 2021. Quantification of proteins involved in intestinal epithelial handling of xenobiotics. Clinical Pharmacology and Therapeutics, 109(4): 1136-1146.

Couto N, Newton JRA, Russo C, Karunakaran E, Achour B, Al-Majdoub ZM, Sidaway J, Rostami-Hodjegan A, Clench MR, Barber J. 2021. Label-free quantitative proteomics and substrate based mass spectrometry imaging of xenobiotic metabolizing enzymes in ex vivo human skin and a human living skin equivalent model. Drug Metabolism and Disposition, 49(1): 39-52.

Al-Majdoub ZM, Achour B, Couto N, Howard M, Elmorsi Y, Scotcher D, Alrubia S, El-Khateeb E, Vasilogianni A-M, Alohali N, Neuhoff S, Schmidt L, Rostami-Hodjegan A, Barber J. 2020. Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain, and skin. FEBS Letters, 594(23): 4134-4150.

Barber J, MR Russell, Rostami-Hodjegan A, Achour B*. 2020. Characterization of CYP2B6 K262R polymorphic variants by quantitative allele-specific proteomics using a QconCAT standard. Journal of Pharmaceutical and Biomedical Analysis, 178, 112901.  

Prasad B, Achour B, Artursson P, Hop CECA, Yurong L, Smith PC, Barber J, Wisniewski JR, Spellman D, Uchida Y, Zientek M, Unadkat JD, Rostami-Hodjegan A. 2019. Toward a consensus on applying quantitative liquid chromatography‐tandem mass spectrometry proteomics in translational pharmacology research: A White Paper. Clinical Pharmacology and Therapeutics, 106(3): 525-543.

Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, Barber J. 2019. Proteomic quantification of human blood-brain barrier drug transporters and solute carriers in healthy individuals and dementia patients. Molecular Pharmaceutics, 16(3): 1220-1233.


Rostami-Hodjegan A, Achour B, Rothman JE. 2021. Methods and apparatus for quantifying protein abundance in tissues via cell free ribonucleic acids in liquid biopsy. Patent number US20210032682A1;

Rostami-Hodjegan A, Achour B. 2022. Methods and apparatus for generating a virtual model of xenobiotic exposure using transcriptomics analysis of liquid biopsy samples. Patent number US20220215898A1;

Rostami-Hodjegan A, Achour B, Smith P. 2022. Methods and apparatus for identifying organ/tissue health status using transcriptomics analysis of liquid biopsy samples. Patent number US20220213560A1;

Rostami-Hodjegan A, Achour B. 2022. Methods and apparatus utilising liquid biopsy to identify and monitor pharmacodynamic markers of disease. UKIPO Patent number 2111504.3.